| __timestamp | ADMA Biologics, Inc. | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 111110000 |
| Thursday, January 1, 2015 | 4311461 | 129714000 |
| Friday, January 1, 2016 | 6360761 | 139574000 |
| Sunday, January 1, 2017 | 29164321 | 218502000 |
| Monday, January 1, 2018 | 42194635 | 322876000 |
| Tuesday, January 1, 2019 | 39504238 | 427320000 |
| Wednesday, January 1, 2020 | 61291426 | 523667000 |
| Friday, January 1, 2021 | 79769341 | 1629000 |
| Saturday, January 1, 2022 | 118814535 | 12079000 |
| Sunday, January 1, 2023 | 169273000 | 35989000 |
Data in motion
In the ever-evolving biotech industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for ADMA Biologics, Inc. and Galapagos NV from 2014 to 2023. Over this period, ADMA Biologics demonstrated a remarkable increase in cost efficiency, with their cost of revenue surging by approximately 4,400%, from $3.7 million in 2014 to $169 million in 2023. In contrast, Galapagos NV experienced a more volatile journey, peaking in 2020 with a cost of revenue of $524 million, before plummeting to $36 million in 2023, a decrease of over 90% from its peak.
This stark contrast highlights the dynamic nature of the biotech sector, where strategic financial management can significantly impact a company's trajectory. Investors and industry analysts should closely monitor these trends to make informed decisions.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Galapagos NV
Cost of Revenue Trends: Zoetis Inc. vs Galapagos NV
Takeda Pharmaceutical Company Limited vs Galapagos NV: Efficiency in Cost of Revenue Explored
BeiGene, Ltd. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: BeiGene, Ltd. vs Galapagos NV
Cost of Revenue: Key Insights for Exelixis, Inc. and ADMA Biologics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs ADMA Biologics, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and ADMA Biologics, Inc.'s Expenses
Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Celldex Therapeutics, Inc.
ACADIA Pharmaceuticals Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Bausch Health Companies Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Galapagos NV and BioCryst Pharmaceuticals, Inc.'s Expenses